Relmada Therapeutics Inc

Market Cap

$756M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$5.72+$1.35 (+30.89%)

Jun 8, 2026

52W High $7.8652W Low $0.54

Company Details

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Ph...

CEO

—

IPO Date

Oct 9, 2014

Website

www.relmada.com

Key Metrics TTM

Revenue

- YoY

Net Income

-$59M

EPS (Diluted)

Free Cash Flow

-$43M

Revenue / Share

$0.00

Gross Margin

Operating Margin

Net Margin

FCF Margin

P/S

P/E

Earnings Reports

Q1 2026

May 12, 2026

FY 2025

Mar 19, 2026

Q4 2025

Mar 19, 2026

Q3 2025

Nov 13, 2025

Q2 2025

Aug 7, 2025

Revenue & Profitability

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee